drugset / Trial / NCT01432626

Pathogenesis of Stress-Induced Cardiomyopathy by I-123 MIBG

NCT01432626 ↗

NaSingle-groupOpen-labelDiagnostic

Summary

Objective: The objective of this pilot study is to characterize the cardiac uptake patterns of I-123 mIBG in stress-induced (Takotsubo's) cardiomyopathy. Hypothesis: Perturbations in sympathetic innervation are the underlying pathogenesis of stress induced cardiomyopathy and will result in abnormalities in I-123 mIBG cardiac imaging. Thus, planar and SPECT I-123 MIBG imaging will provide insight into the pathogenesis of stress-induced cardiomyopathy, and may lead to the development of more specific diagnostic criteria. Study design: This proposal is for a prospective pilot study to characterize perturbations in cardiac sympathetic innervation in patients with stress induced cardiomyopathy by performing planar and SPECT I-123 MIBG imaging during the acute presentation and after recovery of LV function.

Timeline

Start
2011-09
Primary completion
2014-12
Completion
2015-06

Drugs

EvaluationDrugModalityDoseRoute
Subject I-123 radiolabeled metaiodobenzylguanidine Diagnostic / imaging agent 370 mbq Intravenous